Pearson correlation coefficient analysis for associations between clinical, baseline laboratory values, and treatment characteristics with the percentage of fetal hemoglobin at maximally tolerated dose for 53 HUG-KIDS participants
| . | Mean ± 1 SD . | SR r(P) . | PR r (P) . |
|---|---|---|---|
| Age, y | 9.5 ± 3.4 | 0.02 (.90) | 0.02 (.90) |
| Sex, % male | 60.4 | 0.00 (.99) | 0.06 (.66) |
| HbF, % | 6.7 ± 4.2 | 0.43 (.001)* | NA |
| Hemoglobin, g/dL | 7.7 ± 0.9 | 0.34 (.01)* | 0.17 (.24) |
| Mean corpuscular volume, fL | 85.7 ± 6.5 | 0.20 (.15) | 0.12 (.39) |
| RBC count, × 1012/L | 2.65 ± .42 | 0.21 (.13) | 0.11 (.45) |
| Reticulocytes, × 109/L | 365 ± 135 | 0.14 (.31) | 0.28 (.05)* |
| White blood cells, × 109/L | 14.0 ± 3.7 | 0.13 (.37) | 0.28 (.05)* |
| Neutrophils, × 109/L | 7.2 ± 2.8 | 0.14 (.31) | 0.25 (.08) |
| Platelets, × 109/L | 467 ± 155 | 0.10 (.49) | 0.21 (.14) |
| AST, IU/L | 62 ± 25 | − 0.21 (.13) | − 0.10 (.50) |
| ALT, IU/L | 26 ± 11 | − 0.13 (.36) | 0.01 (.97) |
| Total bilirubin, mg/dL | 3.7 ± 2.8 | 0.06 (.67) | 0.15 (.31) |
| LDH, IU/L | 1166 ± 705 | − 0.20 (.16) | − 0.17 (.23) |
| Creatinine, mg/dL | 0.4 ± 0.1 | 0.13 (.37) | 0.09 (.52) |
| Mean MTD, mg/kg/d | 26.2 ± 5.6 | 0.33 (.02)* | 0.45 (< .001)* |
| No. of toxicities | 4.2 ± 3.3 | − 0.14 (.31) | − 0.24 (.10) |
| Noncompliance, % pills returned | 5.6 ± 4.0 | − 0.32 (.02)* | − 0.38 (.007)* |
| . | Mean ± 1 SD . | SR r(P) . | PR r (P) . |
|---|---|---|---|
| Age, y | 9.5 ± 3.4 | 0.02 (.90) | 0.02 (.90) |
| Sex, % male | 60.4 | 0.00 (.99) | 0.06 (.66) |
| HbF, % | 6.7 ± 4.2 | 0.43 (.001)* | NA |
| Hemoglobin, g/dL | 7.7 ± 0.9 | 0.34 (.01)* | 0.17 (.24) |
| Mean corpuscular volume, fL | 85.7 ± 6.5 | 0.20 (.15) | 0.12 (.39) |
| RBC count, × 1012/L | 2.65 ± .42 | 0.21 (.13) | 0.11 (.45) |
| Reticulocytes, × 109/L | 365 ± 135 | 0.14 (.31) | 0.28 (.05)* |
| White blood cells, × 109/L | 14.0 ± 3.7 | 0.13 (.37) | 0.28 (.05)* |
| Neutrophils, × 109/L | 7.2 ± 2.8 | 0.14 (.31) | 0.25 (.08) |
| Platelets, × 109/L | 467 ± 155 | 0.10 (.49) | 0.21 (.14) |
| AST, IU/L | 62 ± 25 | − 0.21 (.13) | − 0.10 (.50) |
| ALT, IU/L | 26 ± 11 | − 0.13 (.36) | 0.01 (.97) |
| Total bilirubin, mg/dL | 3.7 ± 2.8 | 0.06 (.67) | 0.15 (.31) |
| LDH, IU/L | 1166 ± 705 | − 0.20 (.16) | − 0.17 (.23) |
| Creatinine, mg/dL | 0.4 ± 0.1 | 0.13 (.37) | 0.09 (.52) |
| Mean MTD, mg/kg/d | 26.2 ± 5.6 | 0.33 (.02)* | 0.45 (< .001)* |
| No. of toxicities | 4.2 ± 3.3 | − 0.14 (.31) | − 0.24 (.10) |
| Noncompliance, % pills returned | 5.6 ± 4.0 | − 0.32 (.02)* | − 0.38 (.007)* |
Calculations for LDH and PR r are based on only 52 patients.
HUG-KIDS indicates pediatric hydroxyurea safety trial; SR r, simple correlation; PR r, partial correlation adjusting for baseline percentage of fetal hemoglobin (%HbF); HbF, fetal hemoglobin; NA, not applicable; RBC, red blood cell; AST, aspartate aminotransferase; ALT, alanine aminotransferase; LDH, lactate dehydrogenase; and MTD, maximally tolerated dose.
Significant associations.